GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

luvometinib   Click here for help

GtoPdb Ligand ID: 13495

Synonyms: Example 6 [WO2014169843]
Approved drug
luvometinib is an approved drug
Compound class: Synthetic organic
Comment: The chemical structure for luvometinib was obtained from WHO proposed INN list 131 (August 2024). The INN document records luvometinib as a mitogen-activated protein kinase (MEK) inhibitor and antineoplastic agent. It is one of the compounds claimed in patent WO2014169843A1 (Fochon Pharmaceutical) [4]. Fochon Pharmaceutical have one MEK inhibitor in their declared development pipeline, FCN-159. Published information about FCN-159 indicates that it is an orally available MEK1/2 inhibitor lead for the treament of BRAF- or RAS-driven tumours [2-3]. Inhibition of MEK1/2 disrupts downstream MAPK signalling that is activated by upstream mutant RAF/RAS enzymes in malignancies.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 119.56
Molecular weight 665.45
XLogP 2.71
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CN1C2=C(C(=C(C1=O)F)NC3=CC=C(C=C3F)I)C(=O)N(C4CC4)N=C2C5=CC=CC(=C5)NS(=O)(=O)C6CC6
Isomeric SMILES CN1C2=C(C(=C(C1=O)F)NC3=C(C=C(C=C3)I)F)C(=O)N(N=C2C4=CC(=CC=C4)NS(=O)(=O)C5CC5)C6CC6
InChI InChI=1S/C26H22F2IN5O4S/c1-33-24-20(23(21(28)26(33)36)30-19-10-5-14(29)12-18(19)27)25(35)34(16-6-7-16)31-22(24)13-3-2-4-15(11-13)32-39(37,38)17-8-9-17/h2-5,10-12,16-17,30,32H,6-9H2,1H3
InChI Key RJFDJJABNSVLRB-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Keam SJ. (2025)
Luvometinib: First Approval.
Drugs, 85 (9): 1177-1183. [PMID:40751881]
2. Mao L, Guo J, Zhu L, Jiang Y, Yan W, Zhang J, Hui AM, Yang Y, Diao L, Tan Y et al.. (2022)
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma.
Eur J Cancer, 175: 125-135. [PMID:36113242]
3. Tan Y, Cui A, Qian L, Li C, Wu Z, Yang Y, Han P, Huang X, Diao L. (2023)
Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics.
Front Pharmacol, 14: 1101991. [PMID:36755948]
4. Wang W, Zhao X, Yuan Q, Shi H, Tian Q, Liu Q, Zhou Z, Wang X, Chen Z, Chen L et al.. (2014)
Certain protein kinase inhibitors.
Patent number: WO2014169843A1. Assignee: Shanghai Fochon Pharmaceutical Co Ltd. Priority date: 18/04/2014. Publication date: 23/10/2014.